Dis-CoV-er
Research type
Research Study
Full title
Dis-CoV-er: Developing a COVID-19 risk stratification tool for cancer patients based on an investigation of SARS-CoV-2 exposure and handling.
IRAS ID
285060
Contact name
Nagesh Kalakonda
Contact email
Sponsor organisation
Clatterbridge Cancer Centre
Duration of Study in the UK
1 years, 2 months, 0 days
Research summary
Research Summary
The emergence and establishment of the COVID-19 pandemic and ‘social-distancing’ and ‘travel restriction’ measures are impacting delivery of cancer care, treatment decisions and outcomes. To understand the true impact of the pandemic a more comprehensive testing strategy 1) to establish infection rates and 2) assessment of immunological responses to viral exposure is essential.
Patients attending hospitals (CCC and CH) for essential inpatient, outpatient, day care or treatment episodes whose SARS-CoV-2 infection status is unknown or previously negative will be invited to participate in this study. Viral swabs and blood samples will be obtained at presentation and after an interval. The samples will be biobanked and analysed at the end of the recruitment period (1000 patients; 6 – 10 weeks). Consent will be sought for access to anonymised demographic and clinical data to draw conclusions regarding exposure, susceptibility, and immune responses to SARS-CoV-2 and associated risk factors.Summary of Results
No Lay Summary of results has been preparedREC name
East of England - Essex Research Ethics Committee
REC reference
20/EE/0171
Date of REC Opinion
22 Jul 2020
REC opinion
Further Information Favourable Opinion